US2002091137A1PendingUtilityA1

Use of CCI-779 as an antineoplastic agent

45
Assignee: AMERICAN HOME PRODPriority: Nov 15, 2000Filed: Nov 13, 2001Published: Jul 11, 2002
Est. expiryNov 15, 2020(expired)· nominal 20-yr term from priority
Inventors:Gary DukartJames GibbonsLisa SpeicherPhilip FrostCarolyn Discafani-Marro
A61P 35/00A61P 13/12A61K 31/4745A61K 31/436
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides the use of CCl-779 in the treatment of neoplasms.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCl-779.  
     
     
         2 . A method of treating a refractory neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCl-779.  
     
     
         3 . The method according to  claim 1 , wherein the neoplasm is renal cancer.  
     
     
         4 . The method according to  claim 1 , wherein the neoplasm is soft tissue sarcoma.  
     
     
         5 . The method according to  claim 1 , wherein the neoplasm is breast cancer.  
     
     
         6 . The method according to  claim 1 , wherein the neoplasm is a neuroendocrine tumor of the lung.  
     
     
         7 . The method according to  claim 1 , wherein the neoplasm is cervical cancer.  
     
     
         8 . The method according to  claim 1 , wherein the neoplasm is uterine cancer.  
     
     
         9 . The method according to  claim 1 , wherein the neoplasm is a head and neck cancer.  
     
     
         10 . The method according to  claim 1 , wherein the neoplasm is glioblastoma.  
     
     
         11 . The method according to  claim 1 , wherein the neoplasm is non-small cell lung cancer.  
     
     
         12 . The method according to  claim 1 , wherein the neoplasm is prostate cancer.  
     
     
         13 . The method according to  claim 1 , wherein the neoplasm is pancreatic cancer.  
     
     
         14 . The method according to  claim 1 , wherein the neoplasm is lymphoma.  
     
     
         15 . The method according to  claim 1 , wherein the neoplasm is melanoma.  
     
     
         16 . The method according to  claim 1 , wherein the neoplasm is small cell lung cancer.  
     
     
         17 . The method according to  claim 1 , wherein the neoplasm is ovarian cancer.  
     
     
         18 . The method according to  claim 1 , wherein the neoplasm is colon cancer.  
     
     
         19 . The method according to  claim 1 , wherein the neoplasm is endometrial cancer.

Join the waitlist — get patent alerts

Track US2002091137A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.